A Novel RNA Helicase Inhibitor to Treat Breast Cancer

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation. Public reporting burden for this c ollection of information is esti mated to average 1 hour per res ponse, including the time for reviewing instruc tions, searching existing data sources, gathering and mai ntaini ng the data needed, and completing and reviewing this collecti on of information. Send c omments regarding this burden esti mate or an y other as pect of this c ollection of information, including suggestions for reducing this burden to Department of Defense, Washi ngton H eadquarters Ser vices, Directorate for Information Operations and R eports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. R espondents should be awar e that notwithstandi ng any other provision of law, no pers on s hall be s ubject to any penalty for failing to c ompl y with a coll ection of infor mati on if it does not di splay a currentl y valid OMB c ontrol number. In this funding cycle, we concentrated on encapsulating NZ51 int o nanoparticles that are biocompatible and biodegradable. Earlier, we had reported that we were successful in preparing PLGA nanoparticles loaded with GdDTPA-BOA and superparamagnetic iron oxide (SPIO) nanoparticles. Based on that technology, we initiated experiments to load PLGA nanoparticles with NZ51. After a series of experiments, we concluded that there was significant variation from batch to batch preparation and we have to refine the technology used. Currently, we are attempting to encapsulate the RNA helicase inhibitor into a different nanoparticle, such as PLGA nanoparticles composed of low molecular weight copolymers, or nanoparticles composed of chitosan derivatives, with the goals of achieving a faster release resulting in increased efficacy for breast cancer treatment. Also, we are in the proc ess to determine why the different batches made have different aggregation properties in mouse plasma. Furthermore, we are attempting to encapsulate a different DDX3 inhibitor into PLGA nanoparticle to evaluate if the chemical structure of NZ51 is in anyway interfering with the formulation and utility in in vivo experiments.